Johnson & Johnson says it will pay up to $5.5 billion to settle most remaining U.S. talc ovarian cancer lawsuits
The facts
- Johnson & Johnson said it will pay up to $5.5 billion in a proposed settlement to resolve lawsuits alleging that its talc products, including baby powder, caused ovarian cancer.
- The proposed deal is intended to resolve tens of thousands of remaining U.S. talc-related ovarian cancer claims pending in federal and state courts.
- Multiple reports say the settlement would cover about 76,000 claims, representing nearly all of the remaining ovarian cancer talc cases against Johnson & Johnson.
- Johnson & Johnson has denied that its talc-based products caused cancer even as it moved to settle the litigation.
- The settlement will become final only if at least 95% of ovarian cancer claimants in state or federal court agree to it.
- The agreement matters because it could bring to a close a legal battle over Johnson & Johnson's talc products that has lasted for about a decade or longer.
- What remains unresolved is whether enough claimants will accept the deal for it to take effect.
Context
What claims are covered by this settlement?
The proposed settlement covers lawsuits alleging that Johnson & Johnson's baby powder and other talc products caused ovarian cancer, including claims in federal multidistrict litigation and related state-court cases Aol,BBC,Investing.com.
Is the settlement final now?
No. Johnson & Johnson said the agreement becomes final only if at least 95% of ovarian cancer claimants in state or federal court accept it Aol,EL PAÍS,Yahoo! Finance.
What is Johnson & Johnson's position on the allegations?
Johnson & Johnson says the allegations are without merit and continues to deny that its talc products caused cancer, while saying it is settling to put the litigation behind it BBC,BBC,Indian Express.
Common ground, and where they split
- Common ground
- A decade-long talc fight should end only through a settlement broad enough to deliver real closure, with claimant consent determining whether this deal can finally stick.
- Where Left and Right split
- Harmed claimants getting fair closure despite corporate power, or mass litigation earning legitimacy only through overwhelming consent and finality.
How left and right read it
Johnson & Johnson is offering up to $5.5 billion to settle roughly 76,000 ovarian cancer claims tied to its talc products while still denying those products caused cancer. That combination matters. When a decade-long fight on this scale can end only if 95% of claimants agree, the core question is whether people who say they were harmed are getting real closure rather than being asked to absorb the imbalance of power.
“Landmark deal covers about 76,000 claims and could end contentious, decade-long legal battle” — The Guardian
$5.5 billion and roughly 76,000 claims show the scale of a legal fight that has dragged on for about a decade. Just as important, the deal becomes final only if at least 95% of claimants agree. That is the right test: resolve mass litigation through broad consent and finality, not endless coercion by process.
The receipts — 100 sources
Wire services (5)
Other coverage (95)
A news briefing built to show both sides.
The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.